2017 Fiscal Year Final Research Report
Treatment and prevention of hypercholesterolemia by acceleration of cholesterol catabolism to bile acids.
| Project/Area Number |
15K08084
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Nigata University of Phermacy and Applied Life Sciences |
|---|
Principal Investigator |
Yamato Susumu 新潟薬科大学, 薬学部, 客員研究員 (60057370)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中川 沙織 新潟薬科大学, 薬学部, 准教授 (30410228)
|
|---|
| Research Collaborator |
FUWA Fumiko 新潟薬科大学, 薬学部, 研究補助員
SHIMIZU Miho (OHTA Miho) 新潟薬科大学, 薬学部, 研究補助員
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 胆汁酸 / 異化代謝 / GC-MS / LC-MS/MS / HepG2細胞 / HepaRG細胞 |
|---|
| Outline of Final Research Achievements |
It has become apparent that the evaluation system using cell culture (both HepaRG and HepG2 cell lines) and high sensitive analytical methods (GC-MS and LC-MS / MS ) is useful for the analysis of functional food factor contributing to the treatment and prevention of hypercholesterolemia by acceleration of cholesterol catabolism to bile acid. And then, we have found several compounds (cyanidin, probucol, swertiamarin, epigallocatechin and β-sitosterol) to promote the cholesterol catabolism to bile acids by this evaluation system.
|
| Free Research Field |
臨床分析化学
|
